These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 34334713)

  • 1. Re-induction with intravenous Ustekinumab after secondary loss of response is a valid optimization strategy in Crohn's disease.
    Ten Bokkel Huinink S; Biemans V; Duijvestein M; Pierik M; Hoentjen F; West RL; van der Woude CJ; de Vries AC
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e783-e788. PubMed ID: 34334713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy.
    Bermejo F; Jiménez L; Algaba A; Vela M; Bastida G; Merino O; López-García A; Melcarne L; Rodríguez-Lago I; de la Maza S; Bouhmidi A; Barreiro-de Acosta M; López-Serrano P; Carrillo-Palau M; Mesonero F; Orts B; Bonillo D; Granja A; Guerra I
    Inflamm Bowel Dis; 2022 Jan; 28(1):41-47. PubMed ID: 33528018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or continuous multiple intravenous re-induction in Crohn's disease patients who lost response to ustekinumab: Evidence from real-world data.
    Tang J; Li Q; Huang Z; Shi L; Guo Q; Li M; Gao X; Chao K
    Dig Liver Dis; 2024 May; 56(5):749-755. PubMed ID: 38281871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Ren H; Kang J; Wang J; Su J; Zou L; Yin A; Li J; Zhou Q; Wang W; Tang Z; Zhang J; Lu Y; Yang Y; Qiu C; Ding Y; Dong W; An P
    Inflamm Bowel Dis; 2024 Aug; 30(8):1295-1302. PubMed ID: 37619248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study.
    Thomas PWA; van Caem M; West RL; Russel MGVM; Jansen JM; Römkens TEH; Hoentjen F;
    Eur J Gastroenterol Hepatol; 2023 Mar; 35(3):261-269. PubMed ID: 36708296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
    Sandborn WJ; D'Haens GR; Reinisch W; Panés J; Chan D; Gonzalez S; Weisel K; Germinaro M; Frustaci ME; Yang Z; Adedokun OJ; Han C; Panaccione R; Hisamatsu T; Danese S; Rubin DT; Sands BE; Afzali A; Andrews JM; Feagan BG;
    Gastroenterology; 2022 May; 162(6):1650-1664.e8. PubMed ID: 35134323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
    Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
    N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort.
    Plevris N; Fulforth J; Siakavellas S; Robertson A; Hall R; Tyler A; Jenkinson PW; Campbell I; Chuah CS; Kane C; Veryan J; Lam WL; Saunders J; Kelly C; Gaya D; Jafferbhoy H; Macdonald JC; Seenan JP; Mowat C; Naismith G; Potts LF; Sutherland DI; Watts D; Arnott I; Bain G; Jones G; Lees CW
    J Gastroenterol Hepatol; 2021 Aug; 36(8):2067-2075. PubMed ID: 33381875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
    Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
    Chaparro M; Baston-Rey I; Fernández-Salgado E; González García J; Ramos L; Diz-Lois Palomares MT; Argüelles-Arias F; Iglesias Flores E; Cabello M; Rubio Iturria S; Núñez Ortiz A; Charro M; Ginard D; Dueñas Sadornil C; Merino Ochoa O; Busquets D; Iyo E; Gutiérrez Casbas A; Ramírez de la Piscina P; Boscá-Watts MM; Arroyo M; García MJ; Hinojosa E; Gordillo J; Martínez Montiel P; Velayos Jiménez B; Quílez Ivorra C; Vázquez Morón JM; María Huguet J; González-Lama Y; Muñagorri Santos AI; Amo VM; Martín-Arranz MD; Bermejo F; Martínez Cadilla J; Rubín de Célix C; Fradejas Salazar P; San Román AL; Jiménez N; García López S; Figuerola A; Jiménez I; Martínez Cerezo FJ; Taxonera C; Varela P; de Francisco R; Monfort D; Molina Arriero G; Hernández Camba A; García-Alonso FJ; Van Domselaar M; Pajares Villarroya R; Núñez A; Rodríguez Moranta F; Marín-Jiménez I; Robles Alonso V; Martín Rodríguez MDM; Camo-Monterde P; García Tercero I; Navarro Llavat M; Arias García L; Hervías Cruz D; Sulleiro S; Novella C; Vispo E; Barreiro-de Acosta M; Gisbert JP
    Inflamm Bowel Dis; 2022 Nov; 28(11):1725-1736. PubMed ID: 35166347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
    Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort.
    Af Björkesten CG; Ilus T; Hallinen T; Soini E; Eberl A; Hakala K; Heikura M; Jussila A; Koskela R; Koskinen I; Moilanen V; Nielsen C; Nieminen U; Nuutinen H; Heikkinen M; Suhonen UM; Tillonen J; Utriainen K; Vihriälä I; Wennerström C; Borsi A; Nissinen R; Koivunen MR; Sipponen T
    Eur J Gastroenterol Hepatol; 2020 Dec; 32(12):1507-1513. PubMed ID: 32868649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
    Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.